Insmed Incorporated


Cowen Sees High 80% Probability of FDA Approval for Insmed Incorporated’s (INSM) NTM Drug

Insmed’s lead asset ALIS poses compelling prospects for commercial success in the U.S.

Billionaire Izzy Englander Bets on Kratos Defense & Security Solutions, Inc (KTOS), Sarepta Therapeutics Inc (SRPT) and Insmed Incorporated (INSM)

This hedge fund guru has made the right call on these three booming stocks.

Tuesday’s Biotech Insights: Insmed Incorporated (INSM), BioCryst Pharmaceuticals, Inc. (BCRX), Cellect Biotechnology Ltd (APOP)

These 3 pharmas are rising on positive clinical results data

Here’s Why Insmed Incorporated (INSM) Shares Skyrocket Today

Great news from ALIS phase 3 sends Insmed stock into orbit

Company Update (NASDAQ:INSM): Insmed Incorporated Reports 3Q:16 Financial Results and Provides Business Update

Insmed Incorporated (NASDAQ:INSM) reported financial results for the quarter ended September 30, 2016 and provided a business update. Business Update Achieved enrollment objective …

Stock Update (NASDAQ:INSM): Insmed Incorporated Announces Publication of Phase 2 Study of ARIKAYCE in Treatment-Refractory Nontuberculous Mycobacterial Lung Disease

Insmed Incorporated (NASDAQ:INSM) announced the online publication of data from its phase 2 study of ARIKAYCE™ (liposomal amikacin for inhalation or LAI) in the …

Stock Update (NASDAQ:INSM): Insmed Incorporated Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor

Insmed Incorporated (NASDAQ:INSM) announced a licensing agreement with AstraZeneca (NYSE:AZN) for global exclusive rights to AZD7986, a novel oral inhibitor of dipeptidyl peptidase I …

Company Update (NASDAQ:INSM): Insmed Incorporated Appoints Roger Adsett as Chief Commercial Officer

Insmed Incorporated (NASDAQ:INSM) announced the appointment of Roger Adsett as chief commercial officer. Mr.

Stock Update (NASDAQ:INSM): Insmed Incorporated Announces Withdrawal of Marketing Authorization Application for ARIKAYCE™ in Europe

Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it has withdrawn its …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts